by Raynovich Rod | Dec 29, 2021 | 2025 Rayno Biopharmaceuticals Portfolio
Update-1 2:30P EST 12/30 …Countertrend rally in small cap biotechs. Who is buying? Daytraders, ETFs or funds? Or just tax loss selling is over. Omicron news dominates healthcare complex. Bounce in ARKG and XBI. Green screen flashes in smaller caps:CYRX, CRSP,...
by Raynovich Rod | Dec 21, 2021 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Update-1 12/27 Strong rally day with record closes S&P up 1.38%, NAZ up 1.39%. Megacaps rule AAPL,FB,GOOG, MSFT. Strongest sectors energy and tech. Santa Claus rally is finally here. Retail sales soar with strong consumer. Healthcare up 1.05% to $140 handle but...
by Raynovich Rod | Dec 13, 2021 | 2025 Rayno Biopharmaceuticals Portfolio
Update-3 12/17…10:51 EDT Good day for a pivot up? Nibbled on some IBB and XBI. Our top large cap pick VRTX continue to run. NAZ up now 0.22%.Volatility rules. Update-2…Powell transitions FED talk through pivot with 2x taper. Potential for 3 rate hikes in...
by Raynovich Rod | Dec 6, 2021 | 2025 Rayno Biopharmaceuticals Portfolio
12/10/21Update-1 A good week with S&P At New Highs despite inflation at 40 year highs at 6.8%. Infotech leading way up. Small cap biotech still lagging near lows for the year. XBI at $110 could not hold mid-week gains. Same pattern for ARKG now at $60.74 near lows...
by Raynovich Rod | Nov 28, 2021 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Update=3 12/3…Another whipsaw day if you are in Tech stocks (Docusign?) or small cap growth. Blame profit taking ,omicron or tough taper talk. But large cap biopharma held up well: ABBV ABT BMY PFE UNH VRTX etc., but not the IBB – you have to be a stock...
by Raynovich Rod | Nov 22, 2021 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Update-2 11/29 …New Rule- after four downgrades at new lows a stock is a buy. VRTX up over 4% today to $191.5. Is an upgrade coming before or after JPMorgan Healthcare? Update-1 11/23/21… Large cap glam techs stocks take a hit in an another sector...
by Raynovich Rod | Nov 12, 2021 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1… 11/17…Vertex (VRTX) rises on good volume.Added to small position. Good value on fwd PE; look for an upgrade or a deal. Strong CF franchise but needs R&D milestone hit. Large Cap Biopharmaceuticals Metrics and Review Stock Performance was...
by Raynovich Rod | Nov 7, 2021 | 2024-25 Life Science Portfolios, Biopharmaceuticals, Macro
11/9…at close..NASDAQ lower by 0.6% after 12 day win streak. IBB down 1.34% coinciding with Biden drug pricing proposal? Large caps mixed but no sell-off. Sold my ARKG and XBI trades at about 3% profit. Vaccine stocks weak. Mid-cap focus stocks weak. Mid-cap...
by Raynovich Rod | Oct 31, 2021 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-2 11:30 a EDT 11/5 …Disruption from Pfizer for Coronavirus Stocks: Pfizer shares up 8% on new experimental antiviral pill tea cuts hospitalization rates.Covid vaccine and diagnostics stocks hit hard : BNTX down 19%,MRNA down 21%, QDEL down 6%, REGN down...
by Raynovich Rod | Oct 25, 2021 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-3 11am 10/28 Rally Time! NAZDAQ up 1.22% to 15422. This rally could be signaling Biden getting his economic bill approved without Medicare Drug legislation and less onerous taxes. We’ll see. Apparently all new benefits in the bill are paid for?!...
